Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H33N7O5S.C6H6O3S |
Molecular Weight | 677.792 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.CCOC2=NC=C(C=C2C3=NC4=C(CC)N(CCOC)N=C4C(=O)N3)S(=O)(=O)N5CCN(CC)CC5
InChI
InChIKey=STFRDYSZKVPPQF-UHFFFAOYSA-N
InChI=1S/C23H33N7O5S.C6H6O3S/c1-5-18-19-20(27-30(18)12-13-34-4)22(31)26-21(25-19)17-14-16(15-24-23(17)35-7-3)36(32,33)29-10-8-28(6-2)9-11-29;7-10(8,9)6-4-2-1-3-5-6/h14-15H,5-13H2,1-4H3,(H,25,26,31);1-5H,(H,7,8,9)
Molecular Formula | C23H33N7O5S |
Molecular Weight | 519.617 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H6O3S |
Molecular Weight | 158.175 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/web/drug/1_2089.html | http://adisinsight.springer.com/drugs/800017097
Curator's Comment: description was created based on several sources, including:
http://en.pharmacodia.com/web/drug/1_2089.html | http://adisinsight.springer.com/drugs/800017097
Gisadenafil is a phosphodiesterase V inhibitor in clinical development at Pfizer. It had been in phase II clinical trials for the treatment of Benign prostatic hyperplasia; Chronic obstructive pulmonary disease; Erectile dysfunction; Overactive bladder. Treatment-emergent adverse events were: headache, myalgia, dyspepsia, back pain.
Originator
Sources: http://adisinsight.springer.com/drugs/800017097
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22100260 |
1.23 nM [IC50] | ||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21451120 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
204.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22100260 |
1.43 mg/kg single, oral dose: 1.43 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
GISADENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22100260 |
1.43 mg/kg single, oral dose: 1.43 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
GISADENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22100260 |
0.43 mg/kg single, intravenous dose: 0.43 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
GISADENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21451120 |
unknown, unknown |
GISADENAFIL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg single, intravenous Highest studied dose Dose: 800 mg Route: intravenous Route: single Dose: 800 mg Sources: |
healthy, ADULT n = 8 Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 8 Sources: |
|
100 mg 1 times / day multiple, oral Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.671 |
unhealthy, ADULT n = 64 Health Status: unhealthy Condition: hypertonic bladder Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 64 Sources: Page: p.671 |
PubMed
Title | Date | PubMed |
---|---|---|
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. | 2010 Sep |
|
The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. | 2012 Jan 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20151971
10, 25, 50 or 100 mg once a day for 12 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22100260
Apical to basolateral flux across Caco-2 cell monolayer at 25 uM for Gisadenafil is the apparent permeability coefficient = 16x10^6 cm/s).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:04:20 GMT 2023
by
admin
on
Fri Dec 15 16:04:20 GMT 2023
|
Record UNII |
T4S08274OY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2127
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135564628
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
334827-98-4
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
UU-145
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
DTXSID20187125
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
T4S08274OY
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
300000044520
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL1928262
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY | |||
|
C83729
Created by
admin on Fri Dec 15 16:04:20 GMT 2023 , Edited by admin on Fri Dec 15 16:04:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |